Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Yalcin, N. Demir, O. Kayacan (Ankara, Turkey). Tumor necrosis factor alpha inhibitors and reactivation of tuberculosis. Eur Respir J 2007; 30: Suppl. 51, 1774

Member's Comments

No comment yet.

Related content which might interest you: Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1512-1513 Year: 2015 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1510-1512 Year: 2015 Tuberculosis and tumor necrosis factor alpha antagonist: Our experience Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy Source: Eur Respir J 2014; 44: 1289-1295 Year: 2014 The risk of tuberculosis related to tumour necrosis factor antagonist therapies Source: Annual Congress 2011 - TBNET: tuberculosis research in Europe Year: 2011 The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement Source: Eur Respir J 2010; 36: 1185-1206 Year: 2010 Screening and monitoring of tuberculosis in patients on tumor necrosis factor antagonist therapy Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 Using an interferon-γ assay for the diagnosis of tuberculosis infection before using tumor necrosis factor-α blockers Source: Annual Congress 2007 - Gamma-interferon-based tests to diagnose tuberculosis infection and disease Year: 2007 The levels of tumour necrosis factor-alpha and interleukin-1 in newly diagnosed and multi drug resistant tuberculosis Source: Annual Congress 2004 - Clinical and diagnostic features of tuberculosis Year: 2004 Effects of zinc on the interleukin-1 and tumor necrosis factor in experimental silicosis Source: Eur Respir J 2002; 20: Suppl. 38, 517s Year: 2002 Levels of plasma tumour necrosis factor and soluble tumour necrosis factor receptor in patients with COPD and its relation to glucocorticoid receptor levels Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Tumour necrosis factor and lymphotoxin A polymorphisms: a relationship with COPD and its progression? Source: Eur Respir J 2007; 29: 8-10 Year: 2007 Re-activation of bovine tuberculosis in a patient treated with infliximab Source: Eur Respir J 2008; 32: 229-231 Year: 2008 The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 542s Year: 2006 Tumour necrosis factor gene polymorphisms and childhood wheezing Source: Eur Respir J 2005; 26: 637-646 Year: 2005 A screening for latent tuberculosis infection among candidates to anti-tumor necrosis factor-alpha agents using a whole blood interferon-gamma test Source: Annual Congress 2008 - Interferon-gamma release assay tests for diagnosing tuberculosis infection and disease Year: 2008 Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial Source: Eur Respir J 2014; 43: 295-298 Year: 2004 Implication of leptin, tumor necrosis factor-alpha, interleukin-1 and interleukin-6 in the pathogenesis of wasting in tuberculosis Source: Annual Congress 2006 - Immunology of tuberculosis and diagnosis of tuberculosis infection Year: 2006 Tumor necrosis factor and pulmonary gas transfer in common variable immunodeficiency Source: Eur Respir J 2005; 26: Suppl. 49, 686s Year: 2005 Vascular endothelial growth factor and tumor necrosis factor gene polymorphisms in Turkish patients with sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 353s Year: 2006